Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 52, Issue 4, Pages 530-542Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0091270011400414
Keywords
Mesna; dimesna; transporters; kidney; pharmacokinetics
Categories
Funding
- Canadian Institutes of Health Research
- Ontario Graduate Scholarship
Ask authors/readers for more resources
Mesna and its dimer, dimesna, are coadministered for mitigation of ifosfamide- and cisplatin-induced toxicities, respectively. Dimesna is selectively reduced to mesna in the kidney, producing its protective effects. In vitro screens of uptake and efflux transporters revealed saturable uptake by renal organic anion transporters OAT1, OAT3, and OAT4. Efflux transporters breast cancer resistance protein; multidrug and toxin extrusion 1 (MATE1); multidrug resistance proteins MRP1, MRP2, MRP4, and MRP5; and P-glycoprotein (Pgp) significantly reduced dimesna accumulation. Further investigation demonstrated that renal apical efflux transporters MATE1, MRP2, and Pgp were also capable of mesna efflux. Administration of OAT inhibitor probenecid to healthy subjects significantly increased combined mesna and dimesna plasma exposure (91% +/- 34%) while decreasing the renal clearance due to net secretion (67.0% +/- 12.7%) and steady-state volume of distribution (45.2% +/- 13.4%). Thus, the kidney represents a significant sink of total mesna, whereas function of renal drug transporters facilitates clearance in excess of glomerular filtration rate and likely the presence of active mesna in the urine. Loss of renal transporter function due to genetic variability or drug-drug interactions may decrease the efficacy of chemoprotectants, increasing the risk of ifosfamide- and cisplatin-induced toxicities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available